Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) FCF Margin (2016 - 2025)

Guided Therapeutics' FCF Margin history spans 15 years, with the latest figure at 49.32% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 3315068.0% to 49.32% in Q4 2025 year-over-year; TTM through Dec 2025 was 139.24%, a 1584647.0% increase, with the full-year FY2025 number at 139.5%, up 1584621.0% from a year prior.
  • FCF Margin hit 49.32% in Q4 2025 for Guided Therapeutics, up from 461.67% in the prior quarter.
  • Over the last five years, FCF Margin for GTHP hit a ceiling of 258.33% in Q4 2021 and a floor of 34800.0% in Q2 2021.
  • Historically, FCF Margin has averaged 7840.94% across 5 years, with a median of 1967.42% in 2023.
  • Biggest five-year swings in FCF Margin: plummeted -3215000bps in 2024 and later skyrocketed 3315068bps in 2025.
  • Tracing GTHP's FCF Margin over 5 years: stood at 258.33% in 2021, then crashed by -7958bps to 20300.0% in 2022, then surged by 95bps to 1050.0% in 2023, then crashed by -3062bps to 33200.0% in 2024, then surged by 100bps to 49.32% in 2025.
  • Business Quant data shows FCF Margin for GTHP at 49.32% in Q4 2025, 461.67% in Q3 2025, and 144.44% in Q2 2025.